Aquinox Pharmaceuticals (NASDAQ:AQXP) and LifeVantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.
Volatility and Risk
Aquinox Pharmaceuticals has a beta of -8.37, meaning that its share price is 937% less volatile than the S&P 500. Comparatively, LifeVantage has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.
77.4% of Aquinox Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.3% of LifeVantage shares are owned by institutional investors. 4.0% of Aquinox Pharmaceuticals shares are owned by insiders. Comparatively, 3.9% of LifeVantage shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares Aquinox Pharmaceuticals and LifeVantage’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations for Aquinox Pharmaceuticals and LifeVantage, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aquinox Pharmaceuticals presently has a consensus target price of $26.33, suggesting a potential upside of 979.23%. Given Aquinox Pharmaceuticals’ higher probable upside, equities analysts plainly believe Aquinox Pharmaceuticals is more favorable than LifeVantage.
Valuation and Earnings
This table compares Aquinox Pharmaceuticals and LifeVantage’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aquinox Pharmaceuticals||N/A||N/A||-$50.18 million||N/A||N/A|
|LifeVantage||$203.20 million||1.04||$5.76 million||$0.51||28.88|
LifeVantage has higher revenue and earnings than Aquinox Pharmaceuticals.
LifeVantage beats Aquinox Pharmaceuticals on 6 of the 9 factors compared between the two stocks.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
LifeVantage Corporation engages in the identification, research, development, and distribution of nutraceutical dietary supplements and skin care products. The company offers Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skin care product; Axio, a line of energy drink mixes; Omega+, a fish oil dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and Vitamin D3; and PhysIQ, a weight management system, as well as Petandim for Dogs, a companion pet supplement formulated to treat oxidative stress in dogs. It also provides skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, and micro-lift serums; and Hair Care System under the TrueScience brand name. The company sells its products through a direct sales model, as well as a network of independent distributors in the United States, Japan, Hong Kong, Australia, Canada, Mexico, Thailand, the United Kingdom, the Netherlands, Germany, and Taiwan. LifeVantage Corporation is headquartered in Sandy, Utah.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.